Interferon-β stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 843-852

  Kraus, Jörg ^a,b   Voigt, K ^c   Schuller, A M ^d   Scholz, M ^e   Kim, K S ^f   Schilling, M ^b   Schabitz W R ^b   Oschmann, P ^c   Engelhardt, B ^g  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Blood brain barrier; Cell culture; Endothelial cells; Immunology; Interferon ; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL ASSAY; CELL LINE; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID MONOLAYER; MEMBRANE STABILIZATION; NONHUMAN; RETREATMENT; SPECIES DIFFERENTIATION; TRANSENDOTHELIAL ELECTRICAL RESISTANCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CATTLE; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIAL CELLS; HISTAMINE; HISTAMINE AGONISTS; INTERFERON-BETA; MICE; RATS; SPECIES SPECIFICITY; SWINE;

EID: 48349131669     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508088940     Document Type: Article

References (38)

1. Lassmann, H, Bruck, W, Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121.
2. Kermode, AG, Thompson, AJ, Tofts P, MacManus, DG, Kendall, BE, Kingsley, DP, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113: 1477-1489.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled Tial. Neurology 1995; 45: 1277-1285.
4. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
5. Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
6. Antonelli, G, Simeoni, E, Bagnato, F, Pozzilli, C, Turriziani, O, Tesoro, R, et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 1999; 168: 131-136.
7. Lublin, FD, Reingold, SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in: Multiple Sclerosis. Neurology 1996; 46: 907-911.
8. Chofflon, M. Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multi-targeted therapeutic approach? BioDrugs 2005; 19: 299-308.
9. Arnason, BG, Dayal, A, Qu, ZX, Jensen, MA, Genc, K, Reder, AT. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 1996; 18: 125-148.
10. Yong, VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-808.
11. Billiau, A. Interferon beta in the cytokine network: an anti-inflammatory pathway. Mult Scler 1995; 1: S2-S4.
12. Rudick, RA, Ransohoff, RM, Peppler, R, VanderBrug, MS, Lehmann, P, Alam, J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-627.
13. Brod, SA, Marshall, GD, Henninger, EM, Sriram, S, Khan, M, Wolinsky, JS. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46: 1633-1638.
14. Laske, C, Oschmann, P, Tofighi, J, Kuehne, SB, Diehl, H, Bregenzer, T, et al. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol Scand 2001; 103: 105-113.
15. Gaillard, PJ, Der Meide, PH, de Boer, AG, Breimer, DD. Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis. Neuroreport 2001; 12: 2189-2193.
16. Kraus, J, Ling, AK, Hamm, S, Voigt, K, Oschmann, P, Engelhardt, B. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56: 192-205.
17. Meresse, S, Dehouck, MP, Delorme, P, Bensaid, M, Tauber, JP, Delbart, C, et al. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J Neurochem 1989; 53: 1363-1371.
18. Booher, J, Sensenbrenner, M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 1972; 2: 97-105.
19. Cecchelli, R, Dehouck, B, Descamps, L, Fenart, L, Buee-Scherrer, V, Duhem, C, et al. In vitro model for evaluating drug transport across the blood-bron barrier. Adv Drug Deliv Rev 1999; 36: 165-178.
20. Descamps, L, Cecchelli, R, Torpier, G. Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. J Neuroimmunol 1997; 74: 173-184.
21. Franke, H, Galla, H, Beuckmann, CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc 2000; 5: 248-256.
22. Schuller, AM, Windolf, J, Blaheta, R, Cinatl, J, Kreuter, J, Wimmer-Greinecker, G, et al. Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass. Biochem Biophys Res Commun 2005; 329: 616-623.
23. Reiss, Y, Hoch, G, Deutsch, U, Engelhardt, B. T cell interaction with ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells. Eur J Immunol 1998; 28: 3086-3099.
24. Stins, MF, Prasadarao, NV, Ibric, L, Wass, CA, Luckett, P, Kim, KS. Binding characteristics of S fimbriated Escherichia coli to isolated brain microvascular-endothelial cells. Am J Pathol 1994; 145: 1228-1236.
25. Stins, MF, Gilles, F, Kim, KS. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997; 76: 81-90.
26. Siflinger-Birnboim, A, Del Vecchio, PJ, Cooper, JA, Blumenstock, FA, Shepard, JM, Malik, AB. Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 1987; 132: 111-117.
27. Krüger, PG. Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol Appl Neurobiol 2001; 27: 275-280.
28. Ibrahim, MZ, Reder, AT, Lawand, R, Takash, W, Sallouh-Khatib, S. The mast cells-of the multiple sclerosis brain. J Neuroimmunol 1996; 70: 131-138.
29. Fischer, S, Renz D, Schaper, W, Karliczek, GF. Effects of barbiturates on hypoxic cultures of brain derived microvascular endothelial cells. Brain Res 1996; 707: 47-53.
30. Defazio, G, Trojano, M, Ribatti, D, Nico, B, Giorelli, M, De Salvia, R, et al. ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. J Neuroimmunol 1998; 88: 13-20.
31. Huynh, HK, Oger, J, Dorovini-Zis, K. Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60: 63-73.
32. Martin, R. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerois and their application for new therapeutic strategies. J Neural Transm Suppl 1997; 49: 53-67.
33. Hertz, F, Deghenghi, R. Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 1985; 16: 397-403.
34. Bekisz, J, Schmeisser, H, Henandez J, Goldman, ND, Zoon, KC. Human interferons alpha beta and omega. Growth Factors 2004; 22: 243-251.
35. Paty, DW, Li, DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study. Neurology 1993; 43: 662-667.
36. Pozzilli, C, Bastianello, S, Koudriavtseva, T, Gasperini, C, Bozzao, A, Millefiorini, E, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-258.
37. Kraus, J, Bauer, R, Chatzirnanolis, N, Engelhardt, B, Tofighi, J, Bregenzer, T, et al. Interferon-beta(1b) leads to a short-term increase of soluble but long-trem stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004; 251: 464-472.
38. Floris, S, Ruuls, SR, Wierinckx, A, van der Pol, SM, Dopp, E, van der Meide, PH, et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002; 127: 69-79.